[Control of ovulation in the mare with Ovuplant (short-term release of the GnRH analog deslorelin acetate). Overview of investigations from 1990 to 1994].

The study investigates the use of a drug called Ovuplant, a deslorelin short-term release (STI), in controlling ovulation in mares. The research conducted between 1990 and 1994 states that the drug reliably causes ovulation in over 80% of treated mares within 48 hours and does not result in any negative side effects.

Use of Ovuplant in Ovulation Control

• The main focus of the research paper is the use of deslorelin STI, commercially known as Ovuplant, in controlling ovulation in mares. This drug, when used on mares with a follicle size of 30mm or larger while in heat, greatly speeds up the ovulation process. The treated mares are reported to ovulate within 48 hours of administration, which marks a reduction of over 30 hours from the normal ovulation timeline.

Impact on Pregnancy Rates and Twin Pregnancies

• The researchers found that the use of Ovuplant does not have any negative effects on the mare’s ability to become pregnant. Additionally, it does not increase the incidence of early twin pregnancies. Therefore, this treatment can be seen as a safe option to manage ovulation in the mare without causing harm to their reproductive ability.

Side Effects of Ovuplant

• The study reports no considerable side effects from the use of Ovuplant, excluding a short-term local irritation. Furthermore, the treatment can be applied multiple times without losing effectiveness or causing the development of a tolerance in the mare.

Impact on Equine Breeding Industry

• Finally, the research concludes that the use of Ovuplant can have significant benefits for the equine breeding industry. By accelerating ovulation, it reduces the number of breedings needed, saving stallion power, and avoiding unnecessary inseminations. Therefore, this method ensures more efficient and cost-effective ovulation management in mares.